Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare
Citizen Health has secured $30 million in Series A funding led by 8VC, with participation from Transformation Capital and Headline, bringing total funding to $44 million. The company, founded by former Invitae (NYSE: NVTA) executives, is developing an AI-powered healthcare platform focused on rare disease care.
The platform has built 60 engaged communities across 123 rare and complex conditions, partnering with 70+ patient advocacy groups. Key achievements include a 98.3% patient data sharing rate for research, FDA acceptance of their data for regulatory submission, and collaborations with 10+ pharmaceutical partners.
Citizen Health plans to launch its first AI Advocate version in Q3, alongside a new product for patient advocacy groups, focusing on recruiting AI engineers and expanding partnerships.
Citizen Health ha ottenuto 30 milioni di dollari in finanziamento Series A guidato da 8VC, con la partecipazione di Transformation Capital e Headline, portando il finanziamento totale a 44 milioni di dollari. L'azienda, fondata da ex dirigenti di Invitae (NYSE: NVTA), sta sviluppando una piattaforma sanitaria basata sull'IA focalizzata sulla cura delle malattie rare.
La piattaforma ha creato 60 comunit脿 attive in 123 condizioni rare e complesse, collaborando con oltre 70 gruppi di advocacy per i pazienti. Risultati chiave includono un tasso di condivisione dei dati dei pazienti del 98,3% per la ricerca, l'accettazione dei loro dati dalla FDA per una sottomissione regolatoria e collaborazioni con oltre 10 partner farmaceutici.
Citizen Health prevede di lanciare la prima versione dell'AI Advocate nel terzo trimestre, insieme a un nuovo prodotto per i gruppi di advocacy dei pazienti, concentrandosi sul reclutamento di ingegneri IA e sull'espansione delle partnership.
Citizen Health ha conseguido 30 millones de d贸lares en financiaci贸n de Serie A liderada por 8VC, con la participaci贸n de Transformation Capital y Headline, elevando el financiamiento total a 44 millones de d贸lares. La compa帽铆a, fundada por exdirectivos de Invitae (NYSE: NVTA), est谩 desarrollando una plataforma de atenci贸n sanitaria impulsada por IA centrada en el cuidado de enfermedades raras.
La plataforma ha creado 60 comunidades activas en 123 condiciones raras y complejas, asoci谩ndose con m谩s de 70 grupos de defensa del paciente. Logros clave incluyen una tasa de compartici贸n de datos de pacientes del 98,3% para investigaci贸n, la aceptaci贸n de sus datos por la FDA para una presentaci贸n regulatoria y colaboraciones con m谩s de 10 socios farmac茅uticos.
Citizen Health planea lanzar la primera versi贸n de su AI Advocate en el tercer trimestre, junto con un nuevo producto para los grupos de defensa del paciente, enfoc谩ndose en reclutar ingenieros de IA y en ampliar sus alianzas.
Citizen Health臧� 8VC 欤茧弰搿� 3000毵� 雼煬鞚� 鞁滊Μ歃� A 韴瀽毳� 頇曤炒頄堨溂氅�, Transformation Capital瓿� Headline鞚� 彀胳棳頃� 齑� 鞛愱笀鞚� 4400毵� 雼煬臧� 霅橃棃鞀惦媹雼�. Invitae(NYSE: NVTA) 鞝� 鞛勳洂霌れ澊 靹る頃� 鞚� 須岇偓電� 頋穩歆堩櫂 旃橂鞐� 齑堨爯鞚� 毵烄稑 AI 旮半皹 項姢旒�鞏� 頂岆灚韽检潉 臧滊皽頃橁碃 鞛堨姷雼堧嫟.
鞚� 頂岆灚韽检潃 123臧滌潣 頋穩路氤淀暕 歆堩櫂鞐� 瓯胳硱 60臧滌潣 頇滌劚 旎る雼堩嫲毳� 甑稌頄堨溂氅�, 70臧� 鞚挫儊鞚� 頇橃瀽 鞓鬼樃 雼泊鞕� 順戨牓頃橁碃 鞛堨姷雼堧嫟. 欤检殧 靹标臣搿滊姅 鞐瓣惮毳� 鞙勴暅 頇橃瀽 雿办澊韯� 瓿奠湢鞙� 98.3%, 攴滌牅 鞝滌稖鞚� 鞙勴暅 FDA鞚� 雿办澊韯� 靾橃毄, 攴鸽Μ瓿� 10瓿� 鞚挫儊鞚� 鞝滌暯 韺岉姼雱�鞕�鞚� 順戩梾鞚� 鞛堨姷雼堧嫟.
Citizen Health電� 3攵勱赴鞐� 觳� AI Advocate 氩勳爠鞚� 於滌嫓頃橁碃, 頇橃瀽 鞓鬼樃 雼泊毳� 鞙勴暅 鞁犼窚 鞝滍拡霃� 靹犽炒鞚� 瓿勴殟鞚措┌, AI 鞐旍雼堨柎 毂勳毄瓿� 韺岉姼雱堨嫮 頇曥灔鞐� 欤茧牓頃� 鞓堨爼鞛呺媹雼�.
Citizen Health a obtenu 30 millions de dollars en financement de s茅rie A men茅 par 8VC, avec la participation de Transformation Capital et Headline, portant le financement total 脿 44 millions de dollars. La soci茅t茅, fond茅e par d鈥檃nciens dirigeants d鈥橧nvitae (NYSE: NVTA), d茅veloppe une plateforme de sant茅 aliment茅e par l鈥橧A, ax茅e sur la prise en charge des maladies rares.
La plateforme a constitu茅 60 communaut茅s engag茅es couvrant 123 maladies rares et complexes, en partenariat avec plus de 70 associations de patients. Parmi les r茅sultats cl茅s figurent un taux de partage des donn茅es patients de 98,3% pour la recherche, l鈥檃cceptation de leurs donn茅es par la FDA pour une soumission r茅glementaire, et des collaborations avec plus de 10 partenaires pharmaceutiques.
Citizen Health pr茅voit de lancer la premi猫re version de son AI Advocate au troisi猫me trimestre, ainsi qu鈥檜n nouveau produit pour les associations de patients, en se concentrant sur le recrutement d鈥檌ng茅nieurs IA et l鈥櫭﹍argissement des partenariats.
Citizen Health hat unter F眉hrung von 8VC eine Series-A-Finanzierung in H枚he von 30 Millionen US-Dollar erhalten; Transformation Capital und Headline beteiligten sich, womit die Gesamtfinanzierung 44 Millionen US-Dollar betr盲gt. Das Unternehmen, gegr眉ndet von ehemaligen F眉hrungskr盲ften von Invitae (NYSE: NVTA), entwickelt eine KI-gest眉tzte Gesundheitsplattform mit Fokus auf die Versorgung von seltenen Erkrankungen.
Die Plattform hat 60 aktive Communities zu 123 seltenen und komplexen Erkrankungen aufgebaut und arbeitet mit 眉ber 70 Patientenvertretungen zusammen. Zu den wichtigsten Erfolgen z盲hlen eine 98,3%ige Patienten-Datenteilungsrate f眉r die Forschung, die Annahme ihrer Daten durch die FDA f眉r eine beh枚rdliche Einreichung und Kooperationen mit mehr als 10 Pharma-Partnern.
Citizen Health plant, die erste Version seines AI Advocate im dritten Quartal zu starten, zusammen mit einem neuen Produkt f眉r Patientenvertretungen, mit Schwerpunkt auf der Einstellung von KI-Ingenieuren und dem Ausbau von Partnerschaften.
- Secured $30M Series A funding, bringing total funding to $44M since December 2023
- Strong traction with 60 communities across 123 rare conditions and 70+ advocacy group partnerships
- High trust demonstrated by 98.3% patient data sharing rate
- FDA acceptance of data for regulatory submission
- Established partnerships with 10+ pharmaceutical companies
- AI Advocate product still in development, not yet launched
- Requires significant recruitment of technical talent to achieve mission
- Operating in complex regulatory environment with shifting NIH funding
Insights
Citizen Health's $30M Series A funding strengthens Invitae's ecosystem through its founders' connections, potentially enhancing NVTA's rare disease capabilities.
Citizen Health's substantial
The strategic focus on rare diseases鈥攁ffecting over 400 million people globally with
From an investment perspective, the caliber of backers (8VC, Transformation Capital, Headline) adds credibility. The company's AI Advocate concept addresses a genuine pain point in healthcare coordination for complex conditions. Their data platform's FDA acceptance for regulatory submission and pharmaceutical partnerships (10+ companies) suggest potential revenue streams beyond consumer applications.
While not directly impacting Invitae's current operations, the leadership team's previous connection to Invitae could potentially lead to future collaboration or partnership opportunities that might benefit NVTA shareholders, especially given Invitae's focus on genetic testing and rare disease diagnostics. The growing ecosystem of rare disease management tools complements Invitae's testing services.
Founded by Farid Vij (CEO & Co-founder), Nasha Fitter (Chief Business Officer & Co-founder), and a team of industry veterans, Citizen Health is pioneering a new paradigm in healthcare by empowering patients鈥攅specially those with rare and complex conditions鈥攚ith agency, clarity, and actionable insights. The company's platform combines AI, community, and longitudinal health data to help patients interpret medical records, track symptoms, learn from peers, manage appointments, and connect to the next best step in their health journey.
"Today's patients aren't waiting鈥攖hey're searching, deciding, and expecting more," said Farid Vij, CEO and co-founder of Citizen Health. "They deserve the same clarity, personalization, and intelligence in healthcare that they get in every other part of their lives. At Citizen, we're building a personalized AI Advocate for every patient that not only helps people make sense of their health journey, but actually guides them to what they should do next鈥攁nd connects them to it. This is about turning passive systems into proactive, human-centered experiences."
Nearly half of American adults have at least one chronic illness, making self-advocacy especially important.听Citizen's ultimate vision is to provide every patient with a personalized AI Advocate, turning fragmented care into a connected, proactive, and precise experience. They are building agentic AI to take initiative, identifying and acting on opportunities to improve health in ways patients themselves might not anticipate.
"We backed Citizen because they are redefining the care model for patients with complex disease. Citizen's AI advocate is the foundation of a pioneering patient and caregiver experience that is already helping thousands of Americans answer previously unanswerable questions, make informed medical decisions, and accelerate new cures," said Sebastian Caliri, Partner at 8VC who led the Series A round and joined the Citizen Board of Directors.
Vij and Fitter met at their previous company Citizen, which was acquired by Invitae (NYSE: NVTA) in 2021, where Vij was a co-founder. Their new venture, Citizen Health, brings together a leadership team with deep expertise in AI, healthcare, privacy, and consumer technology, with personal motivations rooted in rare disease advocacy and patient empowerment.
"Citizen has truly created a groundbreaking platform that supports individual patients looking to manage rare and complex diseases, while also giving patient advocacy groups a better way to organize their data, and pharma leaders a better way to utilize that data for drug discovery and trials," added Mathias Schilling, Founding Partner at Headline who also invested in the round. "It's rare to see a company combining such expertise in AI and consumer design to impact healthcare, and we're proud to back Farid, Nasha, and the rest of the team."
Citizen Health's Traction and Momentum
- Built over 60 engaged communities across 123 rare and complex conditions
- Partnered with 70+ patient advocacy groups,
70% of which joined organically 98.3% of patients share data for research, reflecting high trust in the platform- Data already accepted by the FDA for regulatory submission
- Collaborating with over 10 pharmaceutical partners
With rare diseases affecting over 400 million people globally and
Citizen Health will launch the first version of its AI Advocate to select communities in Q3, alongside a new product for patient advocacy groups. The company's primary focus is recruiting top AI engineers, product builders, and designers to accelerate its mission, as well as deepening partnerships with pharma, policymakers, and patient organizations.
About Citizen Health
Citizen Health is building the future of healthcare, starting with rare disease. By combining AI, community, and longitudinal data, Citizen empowers patients to take control of their care and contribute to the richest research-grade dataset in healthcare. The company is headquartered in
About 8VC
8VC is a leading technology investment firm. Its partners have co-founded companies including Palantir, Addepar, Resilience, and Saronic, and invested in such healthcare innovators such as Oscar, Cityblock, and Candid Health. 8VC manages over
About Headline
Founded in 1998, Headline is a venture capital firm that partners with fast-growing technology teams to make their success global. With more than
For media inquiries or more information, please contact:
Steven Le
[email protected]听
View original content to download multimedia:
SOURCE Citizen Health
FAQ
How much funding did Citizen Health raise in their Series A round?
What is Citizen Health's main product and when will it launch?
How many patient communities and conditions does Citizen Health support?
What is the connection between Citizen Health and Invitae (NVTA)?
What percentage of patients share their data for research on Citizen Health's platform?
